Life Science News

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) is pleased to announce that Mr. George Ragogna has been appointed Chief Financial Officer (CFO), replacing current Chief Financial Officer (CFO), Mr. Bryan Carson

Mr. Ragogna has over 30 years of experience in the Canadian financial services industry with over 20 years in a progressive leadership role specializing in; strategic planning, corporate sales, workforce optimization and regulatory compliance for the Co-operators Group Limited, a leading Canadian multi-line insurance and financial services co-operative with $56.4 billion in assets under management.

Prior to accepting the position of CFO for Naturally Splendid, Mr. Ragogna successfully managed the sales and service call center of over 550 employees for Co-operators Group Limited, ensuring new and existing staff were trained and knowledgeable in the financial services industry and compliance processes. Mr. Ragogna brings a unique business acumen and strong technical skills that will strengthen Naturally Splendid as the Company focuses on their core business.

Mr. Ragogna states, "I'm excited for the opportunity to support the organization in this next chapter as we transition ourselves into manufacturing our plant-based food entrees. This is a most exciting time as the plant-based protein product industry continues to grow. As a manufacturer, we will deploy innovative strategies to penetrate this expanding market as efficiently as possible and I look forward to implementing these strategies."

Mr. Carson, a co-founder of Naturally Splendid, will retain his position of Vice President as well as his position as a Director of the Company. Mr. Ragogna remains a Director of the Company and Chairman of the Board as well as the position of CFO but will no longer be Chairman of the Audit Committee. The Chairman of the Audit Committee will be assigned to existing Director Mr. Larry Gilmour.

Mr. Gilmour has been appointed Audit Committee Chairman. He has extensive sales and marketing expertise with internationally recognized brands such as: Libby's (Libby, McNeil and Libby); Playtex Corp.; and Black and Decker. Mr. Gilmour has also owned and operated chain grocery outlets including owner/operator of a Super Valu grocery store as well as owner/operator of an IGA grocery store, both of which were located in the Greater Vancouver Area of B.C.

Naturally Splendid CEO Mr. J. Craig Goodwin states, "Company co-founder Bryan Carson and I would like to welcome George to the Company as CFO. We have had the privilege of working with George in his role as Chairman of the Board. Having George step into the CFO role, with his 30 years of experience in the financial sector, is sure to be an asset for the Company. We look forward to supporting George in his new position".

About Naturally Splendid Enterprises Ltd.

Founded in 2010, NSE operates a food manufacturing facility just outside Vancouver, BC in Canada. The Company has established numerous healthy, functional foods under recognized brands such as Natera Sport™, Natera Hemp Foods, CHII, Elevate Me™ and Woods Wild Bar™, and most recently Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment. The Company has a myriad of new products and line extensions under development that are approaching launch. NSE, through an arrangement with Plasm Pharmaceutical, has been approved for conducting a phase 2 clinical trial approved by Health Canada for treatment of COVID-19. NSE has also developed proprietary technologies for the extraction of high-demand, healthy omega 3 and 6 oils from hemp.

NSE contract manufacturers for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many healthy food companies, private labeling a wide variety of nutritional food products destined for global healthy food markets.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-465-0548 (ext. 105)

On Behalf of the Board of Directors
Mr. J. Craig Goodwin CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP - TSX Venture; NSPDF - OTCQB; 50N - Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
E-mail : info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE:Naturally Splendid Enterprises Ltd.



View source version on accesswire.com:
https://www.accesswire.com/685153/George-Ragogna-Appointed-CFO

News Provided by ACCESSWIRE via QuoteMedia

NSP:CA
Naturally Splendid Announces National Food Service Broker Agreement With Tri-Elite Marketing

Naturally Splendid Announces National Food Service Broker Agreement With Tri-Elite Marketing

Naturally Splendid Enterprises Ltd. ("Naturally Splendid") (TSXV:NSP)(OTC PINK:NSPDF)(Frankfurt:50N) is pleased to announce the Company has executed a National Food Service Broker Agreement with Vancouver based Tri-Elite Marketing Ltd. (Tri-Elite), to market the Company's plant-based entrees, PlanteinTM, across Canada

Tri-Elite will focus on securing food service listings across Canada for the Company's extensive line of plant-based, meat alternative entrees. Tri-Elite will be participating with Naturally Splendid at the Canadian Health Food Association (CHFA) trade show this weekend, April 23rd and 24th, promoting the PlanteinTM line to its many existing clients and looking to make connections with new opportunities. Industry experts consider the CHFA trade shows the number one source of presenting new products to retailers doing business in Canada.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Closes Second Tranche of $1,120,456 for a Total Raise of $3,270,971

Naturally Splendid Closes Second Tranche of $1,120,456 for a Total Raise of $3,270,971

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company" ) (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces that it has closed the second tranche of its previously announced non-brokered private placement financing (the "Financing") (see news release dated November 23, 2021 and December 23, 2021) by issuing 37,348,532 Units (each a "Unit") at a price of $0.03 per Unit for gross proceeds of $1,120,455.96 (the "Second Tranche"). In total, the Company has issued 109,032,378 Units for gross proceeds of $3,270,971.34 under the entire private placement financing. The Financing has been oversubscribed by $270,971.34

Each Unit in the Second Tranche consists of one common share of Naturally Splendid and one common share purchase warrant (each a "Warrant"), with each Warrant entitling the holder to purchase one additional common share for a period of two years from the date of the issue at an exercise price of $0.05 per share.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Closes First Tranche of $2,150,515

Naturally Splendid Closes First Tranche of $2,150,515

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company" ) (FRA:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces that it has closed the first tranche of its previously announced non-brokered private placement financing (see news release dated November 23, 2021) by issuing 71,683,846 Units (each a "Unit") at a price of $0.03 per Unit for gross proceeds of $2,150,515 (the "First Tranche

Each Unit in the First Tranche consists of one common share of Naturally Splendid and one common share purchase warrant (each a "Warrant"), with each Warrant entitling the holder to purchase one additional common share for a period of two years from the date of the issue at an exercise price of $0.05 per share.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
NATERA Plant Based Foods Featured at DirectFood.store

NATERA Plant Based Foods Featured at DirectFood.store

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N) (TSXV:NSP) (OTC PINK:NSPDF) is pleased to announce that NATERA Plant-Based Foods is now available through DirectFood.store

DirectFood.store is a British Columbia based food delivery company offering a wide variety of local food throughout the Greater Vancouver Region. The company offers a first-of-its-kind sustainable solution for grocery shopping with a zero-waste system. DirectFood.store does not have any warehouses with all food being picked up directly from the farms or vendors in the morning and delivered to customers later that day.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Reports Third Quarter Results for 2021

Naturally Splendid Reports Third Quarter Results for 2021

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FSE:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the nine months ended September 30, 2021. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid CEO Mr. Craig Goodwin reports, "The Company continues to execute on our strategic plan developing, manufacturing and distributing plant-based, meat alternative entrees. Having identified plant-based entrees as our priority, work has already begun retrofitting our existing food manufacturing facility located in British Columbia. This includes installation of a state-of-the-art packaging line which has already been initiated. This line is expected to be operational in the next 30 - 45 days. Once fully operational, this new packaging line creates significant opportunities in the retail market by providing a wide range of packaging formats that can then be placed in both chiller and freezer sections of grocery stores. The versatility of this packaging line creates opportunities for sales in multiple formats for different placement in stores across a wide range of potential clients, ultimately resulting in increased sales.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Update for Management Cease Trade Order

Naturally Splendid Update for Management Cease Trade Order

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company" ) (FRANKFURT:50N) (TSX-V:NSP) (OTC:NSPDF) announces an update regarding the application to the British Columbia and Alberta Securities Commission to approve temporary management cease trade order ("MCTO") under National Policy 12-203 Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"), which, if granted, will prohibit trading securities by the Company by the Chief Executive Officer and Chief Financial Officer of the Corporation until such time as the Required Filings (defined below) and all continuous disclosure requirements have been filed by the Company, and the MCTO has been lifted. During the period in which the MCTO is effective, the general public, who are not insiders of the Company, will continue to be able to trade in the Company's listed securities

The Company has received approval from the British Columbia and Alberta Securities Commission and the Company anticipates that it will be in a position to remedy the default by filing the Required Filings on or about June 30, 2022. The MCTO will be in effect until the Required Filings are filed.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of IBM, MYPS and AUPH

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff

International Business Machines Corporation (NYSE:IBM)
Class Period: April 4, 2017 - October 20, 2021
Lead Plaintiff Deadline: June 6, 2022

Throughout the class period, International Business Machines Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Strategic Imperatives Revenue and growth, CAMSS and CAMSS Components' revenue and growth, and the Company's Segments' revenue and growth were artificially inflated as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives Revenue; (ii) the Company's present success and positive future growth prospects concerning its Strategic Imperative business strategy were being fueled by the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperative Revenue and, as a result (iii) the Company misled the market by portraying the Company's Strategic Imperative's financial performance and future prospects more favorable than they actually were as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives.

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less
The Gummy Project

Potent Ventures Announces The Gummy Project Selected by Sweets & Snack Expo Committee to Participate in Power Pitch During Sweets & Snacks Expo

Potent Ventures Inc. (CSE: POT) (FSE: 0OS) (OTCQB: POTVF) ("Potent" or the "Company") is pleased to announce that The Gummy Project is one of two companies selected from the show's Startup Street to participate in Power Pitch at Sweets & Snacks Expo on May 24, 2022.

Power Pitch provides selected companies with an opportunity to showcase their products in a sales pitch-style presentation to a panel of leading US retailers, including the following:

Keep reading...Show less

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ABBV, UPST and AXSM

The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery

ABBVie Inc. (NYSE:ABBV)

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting

Late-Breaking TROPiCS-02 Study Results in Heavily Pre-Treated HR+HER2- Metastatic Breast Cancer Patients to be Featured in ASCO Press Program –

New Sub-Analysis from Kite's ZUMA-7 CAR T-cell Therapy Study in Patients Aged 65+ and Data by Tumor Burden Characteristics in Second-Line Large B-cell Lymphoma to be Presented

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against AbbVie, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP(www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against ABBVie, Inc. (ABBVie) (NYSE:ABBV) on behalf of all persons and entities who purchased or otherwise acquired ABBVie securities between April 30, 2021, and August 31, 2021, inclusive (the "Class Period

CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/abbvie-inc?utm_source=PR&utm_medium=link&utm_campaign=abbvie&mktm=r

CANNOT VIEW THIS VIDEO? PLEASE CLICK HERE

TO VIEW OUR COMPLAINT, PLEASE CLICK HERE

LEAD PLAINTIFF DEADLINE: JUNE 6, 2022

CLASS PERIOD: APRIL 30, 2021 through AUGUST 31, 2021

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS: James Maro, Esq. (484) 270-1453 or Email at info@ktmc.com

Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.

ABBVIE'S ALLEGED MISCONDUCT

AbbVie is one of the world's largest pharmaceutical companies. The company's revenues will come under significant pressure in the coming years when its best-selling drug, Humira, will lose patent protection in 2023. Accordingly, AbbVie's future revenue and earnings depend in large part on its ability to develop new sources of revenue to offset Humira's lost sales. Rinvoq-an anti-inflammatory drug manufactured by AbbVie and used to treat rheumatoid arthritis (RA) and other diseases by inhibiting Janus kinase (JAK) enzymes-was touted as one such drug. Rinvoq was initially approved in the United States to treat only moderate to severe RA. However, AbbVie was actively pursuing additional treatment indications and, in 2020, asked the U.S. Food and Drug Administration (FDA) to approve Rinvoq for the treatment of several other diseases.

As is relevant here, Rinvoq is similar to other JAK inhibitor drugs, including Xeljanz, manufactured by Pfizer Inc. When the FDA approved Xeljanz in 2012 for the treatment of RA, it required an additional safety trial to evaluate Xeljanz's risk of triggering certain serious side effects. Beginning in February 2019, the FDA repeatedly warned the public that the safety trial indicated that Xeljanz's use could lead to serious heart-related issue, cancer, and other adverse events. Notwithstanding the similarities between Rinvoq and Xeljanz, during the Class Period, Defendants assured investors that Rinvoq was far safer than Xeljanz and not subject to the same regulatory risks.

However, investors began to learn the truth about Rinvoq's significant risks on June 25, 2021, when AbbVie revealed that the FDA was delaying its review of expanded treatment applications for Rinvoq due to the safety concerns associated with Xeljanz. On this news, the price of AbbVie common stock declined $1.76 per share, or approximately 1.5%, from a close of $114.74 per share on June 24, 2021, to close at $112.98 per share on June 25, 2021.

Then, on September 1, 2021, the FDA announced that final results from the Xeljanz safety trial established an increased risk of serious adverse events, even with low doses of Xeljanz. As a result, the FDA determined that it would require new and updated warnings for Xeljanz and Rinvoq because Rinvoq "share[s] similar mechanisms of action with Xeljanz" and "may have similar risks as seen in the Xeljanz safety trial." The FDA also indicated that it would further limit approved indications for Rinvoq as a result of these safety concerns. On this news, the price of AbbVie common stock declined $8.51 per share, or more than 7%, from a close of $120.78 per share on August 31, 2021, to close at $112.27 per share on September 1, 2021.

After the Class Period, on December 3, 2021, AbbVie announced that the FDA had updated Rinvoq's label to require additional safety warnings and limit marketing of Rinvoq to only its use after treatment with other drugs has failed. On January 11, 2022, Defendants admitted that these changes to Rinvoq's label would negatively impact sales, forcing the Company to reduce its long-term guidance for Rinvoq's sales in 2025.

The complaint alleges that, throughout the Class Period, the Defendants made materially false and/or misleading statements, about the company's business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, Defendants' statements about the company's business, operations, and prospects lacked a reasonable basis, As a result of the Defendants' wrongful acts and omissions, and the significant decline in the market value of AbbVie's securities, AbbVie investors have suffered significant damages.

WHAT CAN I DO?

AbbVieinvestors may, no later than June 6, 2022, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLPor other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages AbbVie investors who have suffered significant losses to contact the firm directly to acquire more information.

CLICK HERE TO SIGN UP FOR THE CASE

WHO CAN BE A LEAD PLAINTIFF?

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP



View source version on accesswire.com:
https://www.accesswire.com/701263/Investor-Reminder-Kessler-Topaz-Meltzer-Check-LLP-Reminds-Investors-of-Deadline-in-Securities-Fraud-Class-Action-Lawsuit-Filed-Against-AbbVie-Inc

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×